Contact Kinegrade
Let’s talk.
Questions about Kinegrade, physical-function assessment, research, partnerships or the company? Get in touch directly.
Direct contact
Start a conversation.
No complicated contact process.
Tell me briefly who you are, what you work on and what you would like to discuss. If a quick conversation is easier, you can book 15 minutes directly.
Reach out about clinical workflows, customer discovery, research, partnerships, investment or Kinegrade more broadly.
What would you like to discuss?
The right next step depends on why you are here.
Kinegrade is still in problem, workflow and commercial validation, so conversations with people close to the problem are particularly useful.
Share how assessment works today.
If you work with strength, mobility, rehabilitation or physical-function assessment, we are actively interviewing healthcare professionals about current workflows.
Take part in an expert interview →Discuss the problem and product direction.
We are interested in speaking with service managers, clinical leads and healthcare decision-makers about reassessment, outcome visibility and physical-function workflows.
Start a healthcare conversation →Explore relevant collaboration.
Research in rehabilitation, ageing, sarcopenia, physical performance, measurement or related areas may overlap with the questions Kinegrade is currently investigating.
Discuss research or partnership →Start the relationship early.
Kinegrade is not currently running a funding round, but we are speaking with relevant health-tech investors and operators as the company develops.
Visit the investor page →Expert interviews
Help us understand the real workflow.
We are currently speaking with healthcare professionals about how physical-function assessment and reassessment work in practice.
The objective is to understand the problem before deciding exactly what Kinegrade should build.
Company
Kinegrade Health
Early-stage health technology company based in Kuopio, Finland.
Kinegrade is currently in pre-validation. Product functionality, intended use and commercial offering remain under development.